AKT1 and non-small cell lung carcinoma: (70) showed no improvement in progression-free survival (PFS) and overall survival (OS) for EGFR-mutated NSCLC treated with enzastaurin (an oral AKT inhibitor) combined with erlotinib compared to erlotinib alone in a phase II study.